Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market
According to the report, the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market was valued at US$ 3.9 Bn in 2022 and is anticipated to expand at a CAGR of 7.2% from 2022 to 2030
Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market
Download Sample @ https://qyresearchmedical.com/sample/111657
EPI is caused by insufficient secretion of pancreatic enzymes such as amylase, lipase, and protease and/ or sodium bicarbonate. Several disorders including different types of diabetes are associated with significantly increased risk for exocrine pancreatic insufficiency (EPI). For instance, according to an article published in Current Diabetes Reports, states that the prevalence of exocrine pancreatic insufficiency (EPI) is higher in type 1 diabetes than in type 2 diabetes. Thus, surge in number of people with diabetes is a key factor anticipated to drive the growth of exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030
This is augmenting the demand for new treatment. To address these demands, the key players are investing in the research and development activities to develop and introduce new exocrine pancreatic insufficiency therapeutics thereby boosting the growth of market. For instance, AzurRx is developing a yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments
Get a glimpse of the in-depth analysis through our Report Brochure
Increase in Prevalence of Chronic Pancreatitis and Cystic Fibrosis Propel Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Growth
Cystic fibrosis is the most common cause of exocrine pancreatic insufficiency. Around 50% of infants with cystic fibrosis have exocrine pancreatic insufficiency at birth, and another 25% develop it within six months. An additional 15% develop exocrine pancreatic insufficiency sometime in childhood or early adulthood.
Thus, rise in the global incidence of cystic fibrosis and chronic pancreatitis is one of the major factors driving the exocrine pancreatic insufficiency therapeutics & diagnostics market
Stringent FDA Regulations to Hamper Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market
Pancreatic enzyme replacement therapy (PERT) using pancrelipase products, which are mostly purified from the porcine pancreas, has been tested widely for exocrine pancreatic insufficiency associated with pancreatic diseases. Pancreatic enzyme products have been available as over-the-counter drugs in many regions for several years.
However, some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is leading to restrain the growth of market
Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Competitive Landscape
This report profiles major players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global exocrine pancreatic insufficiency therapeutics & diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market
- AbbVie, Inc
- Allergan plc.
- Nordmark Arzneimittel GmbH & Co. KG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Cilian AG
- Anthera Pharmaceuticals, Inc
- AzurRx Biopharma, Inc.
Key Questions Answered in Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Report
- What is the scope of growth for product companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
- What will be the Y-o-Y growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market between 2019 and 2027?
- What is the influence of changing trends in technologies on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
- Will North America continue to be the most profitable market for exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics providers?
- Which factors are anticipated to hamper the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market during the forecast period?
- Which are the leading companies in the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market?
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market – Segmentation
Type
- Therapeutics
- Diagnostics
- Blood Tests
- Endoscopic Ultra-sonography (EUS)
- Magnetic Resonance Imaging (MRI)
- CT Scanning
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111657/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/